Merck & Co., Inc. (NYSE:MRK) Hits New 12-Month High – Should You Buy?

Merck & Co., Inc. (NYSE:MRK) shares hit a new 52-week high during mid-day trading on Friday . The company traded as high as $131.59 and last traded at $131.1330, with a volume of 1744882 shares trading hands. The stock had previously closed at $127.63.

Key Headlines Impacting Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck received FDA approval for Lipfendra, the first and only once-daily oral PCSK9 inhibitor, giving the company a new cholesterol treatment with blockbuster potential and improving its diversification story beyond Keytruda. Reuters: Merck’s cholesterol pill gets US FDA approval
• Positive Sentiment: Other coverage said the FDA sign-off could help Merck win share in a large cholesterol-treatment market, with the pill seen as a meaningful alternative to statins and injectables. WSJ: Merck’s first-of-its kind cholesterol pill approved
• Positive Sentiment: Analysts also raised price targets and highlighted Merck’s pipeline setup, suggesting investors see additional upside if upcoming HIV and oncology data continue to land well. Yahoo Finance: Merck’s HIV Pipeline Nears Key Inflection Point
• Neutral Sentiment: Additional articles referenced continued positive sentiment around Merck’s broader health-care momentum and stock performance, but they largely echoed the same FDA catalyst rather than adding new company-specific news. ETF Trends: Use These ETFs as Health Stocks LLY, UNH, MRK Thrive

Analysts Set New Price Targets

MRK has been the subject of a number of research analyst reports. Royal Bank Of Canada reaffirmed an “outperform” rating and issued a $142.00 target price on shares of Merck & Co., Inc. in a report on Wednesday, July 8th. Guggenheim boosted their price target on Merck & Co., Inc. from $140.00 to $145.00 and gave the stock a “buy” rating in a research note on Monday. Wells Fargo & Company upped their price target on Merck & Co., Inc. from $145.00 to $150.00 and gave the stock an “overweight” rating in a report on Wednesday, July 8th. Bank of America raised their price objective on Merck & Co., Inc. from $130.00 to $141.00 and gave the company a “buy” rating in a research note on Tuesday, June 30th. Finally, Citigroup initiated coverage on Merck & Co., Inc. in a research note on Wednesday, May 6th. They issued a “neutral” rating and a $125.00 price objective for the company. One investment analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating and seven have given a Hold rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $133.94.

Merck & Co., Inc. Stock Up 2.3%

The company has a debt-to-equity ratio of 1.02, a current ratio of 1.30 and a quick ratio of 1.06. The firm has a 50-day simple moving average of $119.79 and a two-hundred day simple moving average of $116.86. The company has a market cap of $322.51 billion, a PE ratio of 36.80, a P/E/G ratio of 4.26 and a beta of 0.19.

Merck & Co., Inc. (NYSE:MRK) last issued its quarterly earnings data on Thursday, April 30th. The company reported ($1.28) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.47) by $0.19. Merck & Co., Inc. had a return on equity of 27.55% and a net margin of 13.59%.The business had revenue of $16.29 billion for the quarter, compared to the consensus estimate of $15.85 billion. During the same period in the prior year, the business earned $2.22 earnings per share. The business’s revenue was up 4.9% on a year-over-year basis. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. Research analysts anticipate that Merck & Co., Inc. will post 3.17 earnings per share for the current fiscal year.

Merck & Co., Inc. Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Wednesday, July 8th. Investors of record on Monday, June 15th were paid a $0.85 dividend. The ex-dividend date of this dividend was Monday, June 15th. This represents a $3.40 annualized dividend and a yield of 2.6%. Merck & Co., Inc.’s payout ratio is presently 95.77%.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Somerset Trust Co raised its position in shares of Merck & Co., Inc. by 0.9% in the second quarter. Somerset Trust Co now owns 8,701 shares of the company’s stock valued at $1,118,000 after buying an additional 81 shares during the last quarter. Stonebridge Financial Group LLC lifted its stake in shares of Merck & Co., Inc. by 0.9% during the second quarter. Stonebridge Financial Group LLC now owns 8,747 shares of the company’s stock valued at $1,124,000 after buying an additional 81 shares during the period. Lederer & Associates Investment Counsel CA boosted its position in Merck & Co., Inc. by 0.9% during the second quarter. Lederer & Associates Investment Counsel CA now owns 9,603 shares of the company’s stock worth $1,234,000 after acquiring an additional 84 shares during the last quarter. Pine Haven Investment Counsel Inc boosted its position in Merck & Co., Inc. by 0.6% during the second quarter. Pine Haven Investment Counsel Inc now owns 14,273 shares of the company’s stock worth $1,834,000 after acquiring an additional 86 shares during the last quarter. Finally, Chesapeake Wealth Management boosted its position in Merck & Co., Inc. by 0.6% during the fourth quarter. Chesapeake Wealth Management now owns 14,740 shares of the company’s stock worth $1,552,000 after acquiring an additional 87 shares during the last quarter. 76.07% of the stock is currently owned by hedge funds and other institutional investors.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.